The multi-target small-molecule inhibitor SB747651A shows in vitro and in vivo anticancer efficacy in glioblastomas.

Sci Rep · 2021 · PMC7966768 · PMID 33727611

Europe PMC DOI

hedged sentence

0.0520

closest p · 1.0× alpha

0.0520

boldest claim

The sentences

borderline significantP = 0.052so close (0.05 < p ≤ 0.1)

We found a significant reduction in phosphorylation levels of GSK3α/β (53.4% reduction, P < 0.001), and a borderline significant reduction in CREB (34% reduction, P = 0.052) and mTOR phosphorylation (21.4% reduction, P = 0.062) (Fig. 5 B) after 48 h exposure to 10 μM SB747651A.

also in 11,409 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.